Latest Kidney Disease News

Dimerix Limited is set to conduct a blinded statistical review of its pivotal Phase 3 ACTION3 study in March 2026, aiming to confirm the trial remains powered to demonstrate the primary endpoint of proteinuria reduction in FSGS patients.

Dimerix Limited has completed dosing of the last adult patient in its ACTION3 Phase 3 trial for DMX-200, exceeding its recruitment target and setting the stage for key regulatory milestones.

PYC Therapeutics reported a narrowed half-year loss of $22.8 million while progressing four RNA drug candidates through clinical stages. The company announced a major $653 million capital raising to extend its cash runway to 2030 and support ongoing development.

PYC Therapeutics has initiated a substantial capital raising effort, aiming to secure up to A$653 million to propel its four RNA therapeutic candidates through critical clinical milestones. The retail entitlement offer opens today, following a successful institutional placement.

PYC Therapeutics has launched a A$653 million capital raising to fund the clinical advancement of four RNA-based drug candidates targeting genetic diseases with significant unmet needs. The raise extends the company’s cash runway to 2030, supporting key clinical milestones and a transition to commercialisation.

PYC Therapeutics has launched a substantial $653 million equity raise to fund clinical trials for four promising drug candidates targeting genetic diseases. This capital injection aims to advance the company’s pipeline through critical human efficacy milestones.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

Dimerix Limited has completed recruitment for its pivotal ACTION3 Phase 3 trial targeting a rare kidney disease, secured positive FDA feedback on trial endpoints, and reported a solid cash position of AU$38.5 million at the end of 2025.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.